Evidence map›Paper›PMID 40299108›Full record

ArticleAnnals of intensive care2025

Hemodynamic effects of adjunct arginine vasopressin to norepinephrine in septic shock: insights from a prospective multicenter registry study.

Max Melchers, Vivienne de Smet, Chrissie Rooijakkers, Jonathan Huising, Wander Vermeulen, Beyza Nur Nisa Köktaş, Karlijn Johanna van de Vusse, Kimia Milani Sabzewar, Shakti Bedanta Mishra, Carina Bethlehem and 11 more

Abstract read
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Max MelchersDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Vivienne de SmetDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Chrissie RooijakkersDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Jonathan HuisingDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Wander VermeulenDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Beyza Nur Nisa KöktaşDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Karlijn Johanna van de VusseDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Kimia Milani SabzewarDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Shakti Bedanta MishraDepartment of Intensive Care, Siksha 'O' Anusandhan University Hospital, Bhubaneswar, Odisha, India.
Carina BethlehemDepartment of Intensive Care, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
Dirk P BoerDepartment of Intensive Care, Maasstad Hospital, Rotterdam, the Netherlands.
Nedim CimicDepartment of Intensive Care, Tjongerschans Hospital, Heerenveen, the Netherlands.
Mirella van DuijnhovenDepartment of Intensive Care, Viecuri Medical Center, Venlo, the Netherlands.
Tim FrenzelDepartment of Intensive Care, Radboud University Medical Center, Nijmegen, the Netherlands.
Jordi LiesveldDepartment of Intensive Care, Rivierenland Hospital, Tiel, the Netherlands.
Gianluca PaternosterDepartment of Health Science Anesthesia and ICU School of Medicine, University of Basilicata San Carlo Hospital, Potenza, Italy.
Susanne StadsDepartment of Intensive Care, Ikazia Hospital, Rotterdam, the Netherlands.
Jan J WeeninkDepartment of Intensive Care, Spaarne Gasthuis, Haarlem, the Netherlands.
Barbara Festen-SpanjerDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands.
Peter PickkersDepartment of Intensive Care, Radboud University Medical Center, Nijmegen, the Netherlands.
Arthur Raymond Hubert van ZantenDepartment of Intensive Care, Gelderse Vallei Hospital, Ede, the Netherlands. zantena@zgv.nl.ORCID http://orcid.org/0000-0001-6276-7192

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Surviving Sepsis Campaign guidelines suggest adding arginine vasopressin (AVP) when norepinephrine (NE) doses reach 0.25-0.50 µg/kg/min in septic shock patients. However, relying solely on a NE threshold has limitations, as other factors may be valuable in guiding AVP therapy during septic shock. Therefore, we aimed to identify additional patient characteristics associated with AVP hemodynamic responsiveness.

methodsA multicenter, prospective, observational study was conducted among adult ICU patients who met the predefined criteria for septic shock (not reaching the individual target mean arterial pressure despite adequate fluid resuscitation and NE base dose > 0.25 µg/kg/min) and received AVP therapy. AVP hemodynamic responsiveness was the primary study outcome, defined as stabilization or decrease of NE infusion rate two hours after initiating AVP. Secondary outcomes included shock duration and rebound hypotension following termination of AVP infusion. Univariate and multivariable regression analyses were performed to detect associations between characteristics and outcomes.

resultsBetween May 2020 and October 2023, 200 septic shock patients originating from 11 different ICUs were included. Of these, 153 (79%) met the definition for AVP hemodynamic responsiveness. Obesity and hyperlactatemia was negatively associated with AVP-response (adjusted Odds Ratio [aOR] 0.30, 95%CI 0.14-0.65 and aOR 0.86, 95%CI 0.75-0.99, respectively), while a NE infusion rate ≥ 0.30 µg/kg/min showed positive odds of AVP response (aOR 2.33, 95%CI 1.06-5.14). Incidence of new-onset atrial fibrillation was lower in AVP responders than non-responders (4% vs. 14%, p = 0.013). Higher body mass index (BMI) , NE infusion rate and duration prior to AVP initiation was associated with longer shock duration (aOR 1.06, 95%CI 1.02-1.11, aOR 1.12, 95%CI 1.01-1.25, and 1.01 95% CI 1.00-1.03, respectively), while higher pH associated with lower likelihood of prolonged shock (aOR 0.80, 95%CI 0.64-0.99). Rebound hypotension occurred in 9% when AVP was terminated, and AVP duration > 24 h was negatively associated with rebound hypotension (OR 0.22, 95%CI 0.05-0.85).

conclusionsArterial lactate, pH, BMI, and NE duration and dose were associated with AVP responsiveness and shock duration during septic shock, and rebound hypotension occurred in 9% during recovery. Our findings suggest that beyond NE thresholds, specific factors could be considered to optimize adjunctive AVP therapy in septic shock patients.

Indexed as

Arginine vasopressinBody mass indexIntensive care unitNorepinephrineSepsisShock

Identifiers

PMID40299108
PMCPMC12040798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.